Last reviewed · How we verify
Blank maleate entecavir tablets
Blank maleate entecavir tablets is a Nucleoside reverse transcriptase inhibitor Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently FDA-approved for Chronic hepatitis B infection, Hepatitis B with compensated liver disease, Hepatitis B with decompensated liver disease.
Entecavir inhibits hepatitis B virus reverse transcriptase and protein priming, blocking viral DNA replication.
Entecavir inhibits hepatitis B virus reverse transcriptase and protein priming, blocking viral DNA replication. Used for Chronic hepatitis B infection, Hepatitis B with compensated liver disease, Hepatitis B with decompensated liver disease.
At a glance
| Generic name | Blank maleate entecavir tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Nucleoside reverse transcriptase inhibitor |
| Target | Hepatitis B virus reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Entecavir is a nucleoside analog that competitively inhibits the reverse transcriptase enzyme of hepatitis B virus, preventing the conversion of pregenomic RNA to viral DNA. It also inhibits the protein priming step required for initiation of HBV DNA synthesis. This dual mechanism makes it a potent inhibitor of HBV replication with activity against both wild-type and lamivudine-resistant strains.
Approved indications
- Chronic hepatitis B infection
- Hepatitis B with compensated liver disease
- Hepatitis B with decompensated liver disease
Common side effects
- Headache
- Fatigue
- Dizziness
- Nausea
- Lactic acidosis
- Hepatic flare
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blank maleate entecavir tablets CI brief — competitive landscape report
- Blank maleate entecavir tablets updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about Blank maleate entecavir tablets
What is Blank maleate entecavir tablets?
How does Blank maleate entecavir tablets work?
What is Blank maleate entecavir tablets used for?
Who makes Blank maleate entecavir tablets?
What drug class is Blank maleate entecavir tablets in?
What development phase is Blank maleate entecavir tablets in?
What are the side effects of Blank maleate entecavir tablets?
What does Blank maleate entecavir tablets target?
Related
- Drug class: All Nucleoside reverse transcriptase inhibitor drugs
- Target: All drugs targeting Hepatitis B virus reverse transcriptase
- Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Virology / Hepatology
- Indication: Drugs for Chronic hepatitis B infection
- Indication: Drugs for Hepatitis B with compensated liver disease
- Indication: Drugs for Hepatitis B with decompensated liver disease
- Compare: Blank maleate entecavir tablets vs similar drugs
- Pricing: Blank maleate entecavir tablets cost, discount & access